Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients

OBJECTIVE: To evaluate the clinical significance of TET2 mutation(TET2(mut)) and SNP in adult acute myeloid leukemia (AML) and its effect on prognosis. METHODS: A total of 24 genes, including TET2, FLT3-ITD and NPM1, were detected in 124 adult AML patients using second-generation sequencing technology, and their clinical characteristics and effect on prognosis of patients were analyzed. RESULTS: A total of 25 TET2 gene mutations were detected in 124 AML patients, the mutation rate was 20.2%, there were 75 cases of TET2 single nucleotide polymorphisms(SNP), accounting for 60.5%. There were 47 cases of SNPrs2454206(G>A), accounting for 37.9%. Compared with TET2 wild-type(TET2(wt)) patients, TET2(mut) patients were mostly elderly. TET2SNP was commonly seen in male, with statistically significant differences (P0.05). SNP rs2454206 had no significant correlation with sex and age (P0.05). However, the analysis found that the complete remission rate of 1 course and the total complete rate (CR) of patients with TET2(AG/GG) were both obviously superior to those with TET2(AA) (P0.05). In the univariate analysis, the overall survival(OS) rate of the patients with TET2(mut) was lower than that of patients with TET2(wt), and the event free survival (EFS) rate was higher than that of TET2(wt) patients, but the difference was not statistically significant (P0.05).The 1-year OS rate and EFS rate of the patients with TET2(AA) were significantly lower than those of the patients with TET2(AG/GG) (P0.05). Multivariate analysis showed that TET2(AA) was an independent risk factor for OS and EFS in AML patients. CONCLUSION: TET2 SNPrs2454206(GA) commonly appears in patients with acute myeloid leukemia, and these patients have the better response to chemotherapy and a better prognosis.